Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment

$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

“Across the globe, COVID-19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.

“ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “To date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS-CoV-2 virus and the known variants of concerns in in vitro models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year’s IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic.”

ADG20 COVID-19 Program Highlights

  • New ADG20 Data to be Presented in Multiple Posters during IDWeek: At the IDWeek 2021 Virtual Conference, Adagio plans to present additional data highlighting the potential for ADG20 to provide protection from COVID-19 for up to one year based on its extended half-life in humans combined with its broad and potent neutralizing ability demonstrated in laboratory testing. In addition, the data support the evaluation of a 300mg dose, delivered as a single intramuscular injection, in the ongoing Phase 2/3 STAMP (treatment) and EVADE (prevention) global clinical trials. The data will be presented in multiple posters, which will be available to registered attendees on the virtual platform throughout the duration of the conference, being held from September 29 – October 3, 2021. The presentations include:
    • 1086: A Whole-Body Quantitative System Pharmacology Physicologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 633: Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 1089: Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
    • 1088: A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)
  • Patient Population Expanded in EVADE following IDMC Data Assessment: The independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 recently provided a recommendation to expand Phase 3 trial enrollment to include adolescents 12 years and older and pregnant or nursing women, as well as a decrease in the protocol-specified, in-clinic post injection monitoring time. The IDMC’s recommendations were based on their review of unblinded safety and tolerability data through the Day 28 post-treatment visit from 200 participants enrolled in the Phase 2 lead-in portion of the trial.
  • Partnership with Biocon Biologics Expands the Reach of a Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets: In the second quarter of 2021, Adagio partnered with Biocon Biologics Ltd. to combat the ongoing COVID-19 crisis in southern Asia. The partnership provides Biocon rights to manufacture and commercialize an antibody therapy based on ADG20 in India and additional select emerging markets based on the commercial manufacturing process developed for ADG20. As part of the agreement, Biocon will be granted access to data from Adagio’s Phase 2/3 clinical trials as well as its anticipated Emergency Use Authorization package and other regulatory submissions to support approval or emergency authorization in India and other select emerging markets.

Recent Business Highlights

  • David Hering, Global COVID-19 Vaccine Expert, Appointed as Chief Operating Officer: Adagio recently appointed David Hering as the company’s chief operating officer. Mr. Hering joins Adagio from Pfizer, where he most recently served as the global mRNA business lead, a business specifically created to manage global COVID-19 efforts as well as future vaccines utilizing mRNA technology, and led the launch of the first-ever COVID-19 vaccine in the United States. Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products for COVID-19 and meningococcal and pneumococcal diseases.
  • $355.8 Million Initial Public Offering (IPO) Successfully Completed: In August 2021, Adagio sold 20,930,000 shares of common stock, including the full exercise of the underwriters’ option to purchase an additional 2,730,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds of the offering, before underwriting discounts and commissions and other offering expenses payable by Adagio, were approximately $355.8 million.
  • Collaboration with Scripps: Adagio entered into an exclusive research agreement with The Scripps Research Institute to identify broadly protective vaccine candidates for the prevention of influenza and beta coronaviruses.
  • Board of Directors Expanded with Industry Leaders to Support Future Growth: Adagio recently announced appointments of three industry veterans and area experts to its board of directors:
    • Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC);
    • Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA); and
    • Michael S. Wyzga, president of MSW Consulting, Inc. and former CFO of Genzyme

Second Quarter 2021 Financial Results

  • As of June 30, 2021, Adagio had cash, cash equivalents and marketable securities of $392.5 million, which includes net proceeds from its Series C financing completed in April. Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our initial public offering which closed on August 10, 2021.
  • Research & development expenses including in-process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.
  • Net Loss for the second quarter was $44.7 million, or $0.18 per share.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share amounts)

June 30,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents(1) $ 392,509 $ 114,988
Prepaid expenses and other current assets 3,550 2,394
Total current assets 396,059 117,382
Deferred offering costs 1,933
Total assets $ 397,992 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
Current liabilities:
Accounts payable $ 10,716 $ 8,153
Accrued expenses 27,181 4,919
Total current liabilities 37,897 13,072
Early-exercise liability 8 11
Total liabilities 37,905 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; 16,944,484 shares authorized, issued and outstanding at June 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $505,399 and $169,900 at June 30, 2021 and December 31, 2020, respectively 504,711 169,548
Stockholders’ deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020; 5,599,240 shares issued and outstanding at June 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 1 1
Treasury stock, at cost; 0 shares and 22,600,000 shares at June 30, 2021 and December 31, 2020, respectively (85 )
Additional paid-in capital 4,067 154
Accumulated deficit (148,692 ) (65,319 )
Total stockholders’ deficit (144,624 ) (65,249 )
Total liabilities, convertible preferred stock and stockholders’ deficit $ 397,992 $ 117,382

(1)     Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our issuance and sale of 20,930,000 shares of our common stock in our initial public offering at the price of $17.00 per share after deducting underwriting discounts, commissions and estimated offering costs which closed on August 10, 2021.

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands, except share and per share amounts)

Three Months
Ended
June 30,
Six Months
Ended
June 30,
Period from
June 3, 2020
(Inception) to
June 30,
2021 2021 2020 (3)
Operating expenses:
Research and development(1) $ 35,067 $ 69,204 $ 48
Acquired in-process research and development(2) 2,500 3,500
Selling, general and administrative 7,124 10,695 50
Total operating expenses 44,691 83,399 98
Loss from operations (44,691 ) (83,399 ) (98 )
Other income (expense):
Interest income 23 32
Other expense (5 ) (6 )
Total other income (expense), net 18 26
Net loss and comprehensive loss $ (44,673 ) $ (83,373 ) $ (98 )
Net loss per share attributable to common stockholders, basic and
diluted
$ (0.18 ) $ (0.66 ) $
Weighted-average common shares outstanding, basic and diluted 249,769 125,574 21,250,000

(1)   Includes related-party amounts of $247 for the three months ended June 30, 2021, $435 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(2)   Includes related-party amounts of $2,500 for the three months ended June 30, 2021, $3,500 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(3)   The results for the period from June 3, 2020 (inception) to June 30, 2020 are the same for the three and six months ended June 30, 2020.

‘I Just Cry’: Dying of Hunger in Ethiopia’s Blockaded Tigray

In parts of Ethiopia’s Tigray region, people now eat only green leaves for days. At a health center last week, a mother and her newborn weighing just 1.7 pounds died from hunger. In every district of the more than 20 where one aid group works, residents have starved to death.

For months, the United Nations has warned of famine in this embattled corner of northern Ethiopia, calling it the world’s worst hunger crisis in a decade. Now internal documents and witness accounts reveal the first starvation deaths since Ethiopia’s government in June imposed what the U.N. calls “a de facto humanitarian aid blockade.”

Forced starvation is the latest chapter in a conflict where ethnic Tigrayans have been massacred, gang-raped and expelled. Months after crops were burned and communities stripped bare, a new kind of death has set in.

“You are killing people,” Hayelom Kebede, the former director of Tigray’s flagship Ayder Referral Hospital, recalled telling Ethiopia’s health ministry in a phone call this month. “They said, ‘Yeah, OK, we’ll forward it to the prime minister.’ What can I do? I just cry.”

He shared with The Associated Press photos of some of the 50 children receiving “very intensive care” because of malnutrition, the first such images to emerge from Tigray in months. In one, a small child with startled-looking eyes stares straight into the camera, a feeding tube in his nose, a protective amulet lying in the pronounced hollow of his throat.

Medicines have almost run out, and hospital staffers haven’t been paid since June, Hayelom said. Conditions elsewhere for Tigray’s 6 million people are often worse.

The blockade and the starvation that comes with it mark a new phase in the 10-month war between Tigray forces and the Ethiopian government, along with its allies. Now the United States has issued an ultimatum Take steps to stop the fighting and let aid flow freely, or a new wave of sanctions could come within weeks.

The war began as a political dispute between the prime minister, 2019 Nobel Peace Prize winner Abiy Ahmed, and the Tigrayans who had long dominated Ethiopia’s repressive national government. Since November, witnesses have said, Ethiopian forces and those from neighboring Eritrea looted food sources and destroyed health centers.

In June, the Tigray fighters retook the region, and Ethiopia’s government declared a ceasefire, citing humanitarian grounds. Instead, the government has sealed off the region tighter than ever, fearing that aid will reach the Tigray forces.

More than 350,000 metric tons of food aid are positioned in Ethiopia, but very little of it can get into Tigray. The government is so wary that humanitarian workers boarding rare flights to the region have been given an unusual list of items they cannot bring: Dental flossers. Can openers. Multivitamins. Medicines, even personal ones.

The list, obtained by the AP, also banned means of documenting the crisis, including hard drives and flash drives. Photos and video from Tigray have disappeared from social media since June as aid workers and others, facing intense searches by authorities, fear being caught with them on their devices. Tigray has returned to darkness, with no telecommunications, no internet, no banking services and very little aid.

Ethiopia’s prime minister and other senior officials have denied there is hunger in Tigray. The government has blamed the Tigray forces and insecurity for troubles with aid delivery. It also has accused humanitarian groups of supporting, even arming, the Tigray fighters.

The prime minister’s spokeswoman, Billene Seyoum, did not say when the government would allow basic services to the region. The government “has opened access to aid routes by cutting the number of checkpoints from seven to two and creating air bridges for humanitarian flights,” she said in a statement. But medical supplies on the first European Union air bridge flight were removed during government inspection, and such flights cannot carry the large-scale food aid needed.

In the most extensive account yet of the blockade’s toll, a humanitarian worker told the AP that deaths from starvation are being reported in “every single” district of the more than 20 in Tigray where one aid group operates. The group had run out of food aid and fuel. The worker, like others, spoke on condition of anonymity for fear of retaliation.

“Currently, there are devastating reports coming from every corner,” the aid group wrote to a donor in August, according to documents shared with the AP. “If no urgent solution is found, we will lose many people due to hunger.”

In April, even before the current blockade was imposed, the same group wrote to the donor that “reports of malnourishment are rampant,” and that 22 people in one sub-district had starved to death.

“People’s skin color was beginning to change due to hunger; they looked emaciated with protruding skeletal bones,” the aid group wrote.

In August, another staffer visited a community in central Tigray and wrote that the number of people at risk of starvation was “exponentially increasing” in both rural and urban areas. In some cases, “people are eating only green leaves for days.”

The staffer described speaking with one mother who said her family had been living on borrowed food since June. For the past month, they had eaten only bread with salt. She worried that without food aid in the coming days they would die.

“Finally, we stopped asking her because we could not tolerate to hear additional grim news,” the staffer wrote. “The administrator of the (sub-district) has also told us that there are many families who are living in similar conditions.”

At least 150 people starved to death in August, including in camps for displaced people, the Tigray External Affairs Office has alleged. The International Organization for Migration, the U.N. agency which supports the camps, said: “We unfortunately are not able to speak on this topic.”

Some toilets in the crowded camps are overflowing because there’s no cash to pay for their cleaning, leaving thousands of people vulnerable to outbreaks of disease, a visiting aid worker said. People who ate three meals a day now eat only one. Camp residents rely on the charity of host communities who often struggle to feed themselves.

“People have been able to get by, but barely,” the aid worker said. “It’s worse than subsistence, let’s put it that way.”

Food security experts months ago estimated that 400,000 people in Tigray face famine conditions, more than the rest of the world combined. But the blockade means experts cannot collect the needed data to make a formal declaration of famine.

Such a declaration would be deeply embarrassing for Ethiopia, which in the 1980s seized the world’s attention with a famine so severe, also driven by conflict and government neglect, that some 1 million people were killed. Since then, Africa’s second most populous country had become a success story by pulling millions from extreme poverty and developing one of the world’s fastest-growing economies.

Now the war is hollowing out the economy, and stomachs. Malnutrition rates are near 30% for children under the age of 5, the U.N. World Food Program said Wednesday, and near 80% for pregnant and breastfeeding women.

As the war spreads, so might hunger. Tigray forces have entered the neighboring regions of Amhara and Afar in recent weeks, and some residents accuse them of carrying out acts of retaliation, including closing off supply routes. The Tigray forces deny it, saying they aim to pressure Ethiopia’s government to lift the blockade.

The U.N. human rights office says abuses have been committed by all sides, although to date witness accounts indicate the most widespread atrocities have been against Tigrayan civilians.

There is little help coming. The U.N. says at least 100 trucks with food and other supplies must reach Tigray every day to meet people’s needs. But as of Sept. 8, fewer than 500 had arrived since July on the only accessible road into the region. No medical supplies or fuel have been delivered to Tigray in more than a month, the U.S. says, blaming “government harassment” and decisions, not the fighting.

In mid-September the U.N. issued the first report of its kind showing in red the number of days remaining before cash or fuel ran out for key humanitarian work like treating Tigray’s most severely malnourished. Often, that number was zero.

Some trucks carrying aid have been attacked, and drivers intimidated. In August, a U.N. team trying to pick up staff from Tigray was turned around by armed police who “ordered the drivers to drive significantly over speed limits while verbally abusing, harassing and threatening them,” a U.N. report said.

Major international aid groups like Doctors Without Borders and the Norwegian Refugee Council have had their operations suspended, accused of spreading “misinformation” about the war. Almost two dozen aid workers have been killed, some while distributing food. Some aid workers are forced to ration their own food.

“It is a day-to-day reality to see human sufferings, starvation,” the Catholic bishop of Adigrat, Abune Tesfaselassie Medhin, wrote in a Sept. 3 letter, shared with the AP, appealing to partners overseas for help and warning of catastrophe ahead.

The need for food will continue well into next year, the U.N. says, because the limited crops planted amid the fighting are likely to produce only between a quarter and at most half of the usual harvest.

Grim as they are, the reports of starvation deaths reflect only areas in Tigray that can be reached. One Tigrayan humanitarian worker pointed out that most people live or shelter in remote places such as rugged mountains. Others are in inaccessible areas bordering hostile Eritrea or in western Tigray, now controlled by authorities from the Amhara region who bar the way to neighboring Sudan, a potential route for delivering aid.

As food and the means to find it run out, the humanitarian worker said, “I am sure the people that are dying out of this man-made hunger are way more than this.”

Source: Voice of America

Cameroon Repatriates Nigerian Ex-Fighters, Family Members

More than 850 former Boko Haram fighters and their family members who escaped from the jihadist group to Cameroon have left northern Cameroon for Nigeria. Nigerian authorities say they are taking the former militants to Nigerian disarmament centers after complaints that such centers in Cameroon were overwhelmed by the number of former jihadists defecting since the terrorist group’s leader was declared killed in May.

Hundreds of people Saturday gathered along streets, watching and waving as 20 buses transporting former Boko Haram militants and their families left Mora, a town on Cameroon’s northern border with Nigeria, for Banki, a town in Nigeria’s Borno state.

The governor of Cameroon’s Far North region, Midjiyawa Bakari, said the former militants agreed to voluntarily return to Nigeria.

Bakari said the ex-Boko Haram militants who have agreed to return to Nigeria’s Borno state are Nigerian citizens, 854 of them which also include their families. He said they told Cameroonian government officials that they were either fighters or slaves on plantations controlled by the jihadist group. Bakari said the Nigerian ex-fighters promised to be good citizens of Borno state.

Bakari said about 150 more former militants who are of Nigerian nationality will return to their country in the weeks ahead, but he did not explain why they are not returning now.

A majority of the ex-militants are women and children. Cameroon said more about 320 males [including young boys among them] are former fighters of the jihadist group. 80 are females the terrorist group used as spies in localities they attacked, authorities said. 454 others are their family members.

34-year-old Kadir Hassan said he is spokesperson of the former Boko Haram militants who agreed to return to Nigeria. He escaped from the Sambisa Forest, a Boko Haram stronghold on the Cameroon-Nigeria border in August. The former fighter said he is looking forward to meeting his relatives in Kukawa, a town in Nigeria’s Borno state.

Hassan said he left Kukawa to join the jihadist group in March 2020.

Hassan said many Cameroonians and Nigerians he saw in the Sambisa Forest want to leave Boko Haram but are afraid that fighters will kill them. He said he is pleading with the Multinational Joint Task Force of the Lake Chad Basin that is fighting the jihadist group to help people who are still under Boko Haram captivity and want to leave. He said the ex-combatants pledge to contribute to the development of their communities when they return to Nigeria.

The task force made up of troops from Niger, Cameroon, Chad and Nigeria said it took the surrendered Boko Haram militants to demobilization centers called DDRs in Meri and Meme, Cameroonian towns on the border with Nigeria.

In August, Cameroon said it was negotiating to return the ex-militants to Nigeria as the DDR centers were becoming overcrowded.

Lawan Aba Wakilbe, Nigeria’s Borno state Commissioner for Education, represented the government of Nigeria at the ceremony to hand over the former militants. He said the former militants will be kept at rehabilitation centers in Banki, Nigeria.

“We are going to rehabilitate them, and we will reintegrate them into society. You see taking this number away from Boko Haram has given them a shortage in manpower. We are happy and we would like to use this opportunity to thank the Cameroonian government for keeping and handing them over to us,” he said.

Cameroon says former militants still at the demobilization centers on its northern border with Nigeria and Chad include Chadians, Cameroonians and Nigerians.

Bakari said DDR centers in Cameroon’s northern border will continue to receive militants and fighters who surrender and drop their weapons.

Source: Voice of America

Rwandan Court Finds ‘Hotel Rwanda’ Hero Guilty of Terror-Related Charges

Rwanda’s High Court has sentenced Paul Rusesabagina of “Hotel Rwanda” fame to 25 years in prison after finding him guilty on terrorism-related charges.

Rusesabagina, 67, has denied the charges. He has 30 days to appeal the sentence.

The court convicted and sentenced the hotelier-turned-activist Monday following a trial that critics say was unfair with a pre-determined outcome.

Rusesabagina and 20 others were charged with offenses for their alleged connections to the National Forces of Liberation, or the FLN, a militia group the government accuses of carrying out terrorist attacks in Rwanda.

In announcing the sentence, presiding Judge Antoine Muhima told a Kigali courtroom that Rusesabagina was guilty of creating and being a member of a terrorist organization.

Rwandan Government Spokeswoman Yolande Makolo said on Twitter that evidence against the defendants was “indisputable.”

A state-controlled newspaper had earlier reported that prosecutors were seeking a life sentence for Rusesabagina, a prominent critic of President Paul Kagame and his government.

Family and advocates say Rusesabagina, who left his home country in 1996 and is a Belgian citizen and a U.S. resident, was effectively tricked into returning to Rwanda in August 2020. After flying to the United Arab Emirates city of Dubai, Rusesabagina boarded a private plane and was flown to Kigali, where he was arrested.

Rusesabagina said in interviews after his detention that he believed he was flying to Burundi to speak in churches at the invitation of a friend.

Kate Gibson, one of Rusesabagina’s lawyers, spoke to VOA English to Africa’s Daybreak Africa radio program from Geneva and said Rusesabagina never stood a chance in court.

“It’s our opinion that this is the end of a story that was scripted and written even before Mr. Rusesabagina was kidnapped,” she said. “But there was always a deliberate and decided plan in place that he would be put on trial and convicted by the Rwandan judicial authorities.”

Gibson said Rusesabagina did not receive a fair trial, saying lawyers weren’t allowed to bring documents to him and when documents got through for discussion, they were confiscated. The trial, she said, was “so far below internationally recognized standards for a fair trial that the verdict itself is of no particular consequence.”

Independent observers seem to agree. Representatives from the American Bar Association’s (ABA) Center for Human Rights, who have been monitoring the trial as part of the Clooney Foundation for Justice’s TrialWatch, echoed Gibson’s sentiment.

“This so-called trial is not a real adversarial proceeding: it has become a spectacle in which the state’s version of events is not allowed to be challenged. Any conviction that emerges from it cannot be considered credible as it will be based on evidence that has not been properly examined.” Geoffrey Robertson QC, the TrialWatch Expert said.

“It’s an empty verdict because the proceedings that went before it was so manifestly unfair,” Gibson said. Basic rights such as legal assistance, the right to adequate time and facilities to prepare and the right to be presumed innocent, were denied, she added.

“Days after Paul’s [Rusesabagina] arrest, high ranking members of the Rwandan authorities including the president [Paul Kagame] came out and said that Paul was guilty,” she said.

The United States also issued a statement of concern about the trial and doubt over the verdict, noting in particular Rusesabagina's complaints about the lack of access to his lawyers and documents.

“We urge the Government of Rwanda to take steps to examine these shortcomings in Mr. Rusesabagina's case and establish safeguards to prevent similar outcomes in the future,” U.S. State Department spokesperson Ned Price said in a statement.

Source: Voice of America

Benin Startup Builds Computers Out of Jerricans, Distributes Them at Low Cost

BloLab, a startup in Benin is turning plastic jerricans into computers using recycled components and distributing them to the public at a low cost.

Arthur Dadjo is a student in Cotonou, Benin, where innovation and recycling meet. For the past year, he has been using a computer he built himself. It is made from a plastic jerrycan, recycled materials and parts from an old or broken computer to build what would become the computer’s motherboard and hard drive.

Locals call it “Jerry” after the name of the containers. With royalty-free software installed, it is as good as new. And most importantly, cheaper.

"You can find a complete office computer between 300 and 350,000 in West African CFA franc, the local currency," he said. "But with the components we bought with the help of the startup, we spent about 100 to 150,000 (CFA franc) to have this computer."

BloLab, a digital innovation lab working in the fields of education and digital technology, makes these “Jerry” computers. The startup regularly organizes workshops to teach people how to make their own computers for free.

Medard Agbayazon, the founder of BloLab, says in addition to giving people access to cost effective products, the trainers want to help develop skills in innovation.

The second objective is to stimulate creativity in children. He says when they learn to do these “Jerrys,” they also learn how to solve problems they are confronted with in their environment, using the material or the means they have at their disposal.

Experts believe that the computer is increasingly an indispensable working tool and that initiatives such as BloLab’s should be encouraged.

Ali Shadai, is with Open Nsi, an organization focusing on digital transformation of companies.

"A computer is a door to a world of opportunities,mand making it accessible to the greatest number of people is beneficial for these people and for society in general," he said. "BloLab’s effort is positive."

The training to learn how to build a “Jerry” is offered for free. But participants must find the components to build their own computers themselves.

BloLab has been in operation for 4 years and founders say that hundreds of people have already taken advantage of the training sessions and built their computer.

The startup is now working to make these self-built computers available to schools located in remote areas. With that, BloLab says, it would bridge the digital gap one “Jerry” at a time.

Source: Voice of America